Recombinant Mouse Histamine H4 receptor (Hrh4)

What is the mouse Histamine H4 receptor (mHrh4) and how does it compare to human H4R?

The mouse Histamine H4 receptor (mHrh4) is a G protein-coupled receptor that belongs to the histamine receptor family. Unlike the human H4 receptor (hH4R) which exhibits exceptionally high constitutive activity, the mouse H4 receptor displays significantly lower constitutive activity . This fundamental difference is attributed to key amino acid variations, particularly at positions F169V and S179M in the human versus mouse receptors .

When designing comparative studies between species, researchers should account for these pharmacological differences, as compounds that function as inverse agonists at hH4R may behave as neutral antagonists or partial agonists at mHrh4 . This has significant implications for translational research and drug development strategies.

What are the primary expression patterns of mouse Hrh4 in tissues?

Mouse Hrh4 demonstrates a distinct expression pattern, predominantly in hematopoietic cells . Within the immune system, Hrh4 shows high expression in bone marrow-derived cells and peripheral hematopoietic cells . Specifically, the receptor is abundantly expressed in:

• Macrophages (particularly in inflammatory states)

• Dendritic cells

• Mast cells

• Eosinophils

• Monocytes

Unlike other histamine receptors, Hrh4 has minimal expression in non-immune tissues, making it a valuable target for studying immune-mediated pathologies . Flow cytometry analysis of retinal tissue from diabetic mice showed that macrophages account for the majority of CD45+HRH4+ cells, confirming the predominant expression of Hrh4 in the macrophage population during inflammatory conditions .

What methodologies are used to generate recombinant mouse Hrh4 for research purposes?

Recombinant mouse Hrh4 can be generated through several approaches, with the selection depending on experimental requirements:

• Expression vector systems: Using pVL1392 plasmids containing the mHrh4 gene for transfection in expression systems .

• Sf9 insect cell expression: Co-expression of mHrh4 with Gαi2 and Gβ1γ2 in Sf9 cells provides functional receptor complexes suitable for binding and signaling studies .

• Mammalian cell expression: HEK293 cells can be transfected with expression vectors containing mHrh4 cDNA for stable or transient expression.

• Purification approaches: After expression, membrane preparation followed by detergent solubilization and affinity chromatography can yield purified receptor protein.

The thermal stability of recombinant mHrh4 should be assessed through accelerated thermal degradation tests to determine the loss rate of protein function over time . Additionally, validation of recombinant mHrh4 requires confirmation of ligand binding properties and functional coupling to downstream signaling pathways.

How can I validate the functionality of recombinant mouse Hrh4 in experimental systems?

Validating recombinant mouse Hrh4 functionality requires a multi-parametric approach:

Binding Assays:

• Conduct saturation binding assays using [³H]-histamine to determine receptor density (Bmax) and binding affinity (Kd)

• Perform competition binding assays with known H4R ligands such as JNJ 7777120, thioperamide, and 4-methylhistamine

Functional Assays:

• [³⁵S]-GTPγS binding assays to measure G-protein activation in response to agonists

• Calcium mobilization assays in cells co-expressing chimeric G-proteins

• Measure inhibition of forskolin-induced cAMP accumulation (as H4R couples to Gαi)

• ERK1/2 phosphorylation assays for downstream signaling

Comparative Analysis:
Compare pharmacological profiles with the following reference compounds:

Proper validation should include positive controls (full agonists) and negative controls (non-transfected cells) to confirm specific receptor-mediated responses.

What are the optimal conditions for studying recombinant mouse Hrh4-mediated signaling in vitro?

Optimizing experimental conditions for mouse Hrh4-mediated signaling requires attention to several parameters:

Buffer Composition:

• pH: Maintain at 7.4 for optimal binding kinetics

• Divalent cations: Include 1-2 mM MgCl₂ and 0.1-0.5 mM CaCl₂ to support G-protein coupling

• Sodium concentration: Lower concentrations (50-100 mM) can enhance agonist binding

Cell Systems:

• Recombinant expression: Sf9 insect cells with co-expressed G-proteins provide a clean background

• Primary cells: Bone marrow-derived macrophages (BMDMs) offer a physiologically relevant system

• Culture conditions: For BMDMs, high glucose conditions (25 mM) upregulate Hrh4 expression

Experimental Timing:

• Receptor expression peaks at 48-72 hours post-transfection in most systems

• For inflammation models, treatment with high glucose for 48 hours increases Hrh4 expression in BMDMs

Data Collection Parameters:

• Signaling kinetics: Measure at multiple time points (30 seconds to 30 minutes) to capture both rapid G-protein and delayed β-arrestin-mediated responses

• Concentration range: Test ligands at 10⁻¹⁰ to 10⁻⁵ M to generate complete dose-response curves

A methodological approach for studying chemotaxis mediated by recombinant mHrh4 would include: treating BMDMs with high glucose (25 mM) for 48 hours, pre-incubating with or without antagonist (e.g., JNJ7777120), and then measuring migration towards histamine using Transwell migration assays .

What animal models are appropriate for studying mouse Hrh4 function in vivo?

Several animal models have been validated for studying mouse Hrh4 function:

Diabetic Retinopathy Model:

• Induction: Single intraperitoneal injection of streptozotocin (STZ, 200 mg/kg)

• Assessment: Perform fluorescence-activated cell sorting (FACS) of retinal tissue 12 weeks post-STZ injection to analyze immune cell infiltration

• Intervention: Daily administration of HRH4 antagonist (JNJ7777120) for 4 weeks prior to expected onset of retinopathy

• Readouts: Retinal vascular leakage, macrophage infiltration, inflammatory cytokines

Pruritus Models:

• Acute histamine-induced scratching: Intradermal injection of histamine or selective H4R agonists

• Chronic pruritus: Models of atopic dermatitis using repeated allergen exposure

• Assessment: Quantification of scratching behavior and skin inflammation

• Validation approach: Compare responses in wild-type versus Hrh4-deficient mice

Asthma/Airway Inflammation Models:

• Ovalbumin or house dust mite-induced airway inflammation

• Assessment: Lung function, bronchoalveolar lavage cell counts, cytokine profiling

• Intervention: Prophylactic or therapeutic administration of H4R antagonists

Knockout Validation:
For all models, comparing results between wild-type and Hrh4-knockout mice provides critical validation of receptor-specific effects. Pharmacological validation using selective antagonists (JNJ7777120) at doses of 10-30 mg/kg IP or PO should be performed in parallel .

How do I determine the constitutive activity of recombinant mouse Hrh4 compared to other species orthologs?

Determining constitutive activity of recombinant mouse Hrh4 requires specialized approaches to measure receptor activity in the absence of ligand:

Methodology for Comparative Constitutive Activity Assessment:

• Expression System Preparation:

  • Co-express wild-type or mutant receptors with Gαi2 and Gβ1γ2 in Sf9 cells

  • Prepare membrane fractions from cells expressing equivalent receptor densities

• Basal Activity Measurement:

  • Measure basal [³⁵S]-GTPγS binding in the absence of any ligand

  • Calculate fold-increase in basal activity compared to non-transfected membranes

• Inverse Agonist Response:

  • Test potency and efficacy of inverse agonists (e.g., thioperamide)

  • Greater constitutive activity correlates with higher efficacy of inverse agonists

• Comparative Analysis Template:

• Mutational Analysis:

  • For deeper mechanistic understanding, generate point mutations (V171F in mHrh4 corresponding to F169 in hH4R, and/or M181S corresponding to S179 in hH4R)

  • Measure how these mutations affect constitutive activity

The significant difference in constitutive activity between human and mouse H4R is primarily attributed to differences at positions 169/171 and 179/181, with human F169 being particularly critical for stabilizing the active conformation of the receptor .

What strategies can be used to improve the stability and expression of recombinant mouse Hrh4?

Enhancing stability and expression of recombinant mouse Hrh4 requires specific strategies to overcome the challenges associated with GPCR expression:

Expression Enhancement Strategies:

• Codon Optimization:

  • Optimize codon usage for the expression system (mouse, insect cells, or E. coli)

  • Eliminate rare codons and optimize GC content

• N-terminal Modifications:

  • Add signal sequences (e.g., hemagglutinin signal peptide) to improve membrane targeting

  • Consider fusion partners (maltose-binding protein, thioredoxin) for increased solubility

• Stabilizing Mutations:

  • Introduce specific point mutations that enhance thermostability without affecting function

  • Consider using directed evolution approaches to identify stabilizing mutations

• Expression System Selection:

  • For functional studies: mammalian cells (HEK293, CHO)

  • For structural studies: Sf9 or Sf21 insect cells

  • For high-yield production: specialized strains like Expi293F

Stability Enhancement Approaches:

• Buffer Optimization:

  • Include cholesterol or cholesteryl hemisuccinate (CHS) in membrane preparations

  • Use glycerol (10-20%) as a stabilizing agent

  • Optimize pH and ionic strength based on stability profiles

• Storage Conditions:

  • Store membrane preparations at -80°C with protease inhibitors

  • For purified protein, flash-freeze in small aliquots to avoid freeze-thaw cycles

• Thermal Stability Assessment:

  • Monitor thermal stability through accelerated degradation tests

  • Calculate half-life at different temperatures to predict long-term stability

• Ligand Stabilization:

  • Addition of high-affinity ligands during purification can stabilize the receptor

  • For mouse Hrh4, consider stabilizing with JNJ7777120 or 4-methylhistamine during purification

By implementing these strategies, researchers can achieve 3-5 fold improvements in expression levels and significantly extend the functional half-life of recombinant mouse Hrh4 preparations.

How do pharmacological differences between mouse and human Hrh4 impact translational research and drug discovery?

The pharmacological differences between mouse and human Hrh4 have profound implications for translational research:

Key Species Differences and Their Impact:

• Constitutive Activity Divergence:

  • Human H4R exhibits high constitutive activity while mouse Hrh4 shows minimal constitutive activity

  • Impact: Compounds that are inverse agonists at human H4R may appear as neutral antagonists or even partial agonists at mouse Hrh4

• Ligand Pharmacology Shift:

  • Compounds can display significantly different potency and efficacy profiles between species

  • Impact: Preclinical efficacy in mouse models may not translate directly to human clinical outcomes

• Anatomical Distribution Differences:

  • While both species express the receptor primarily in immune cells, the relative abundance in specific immune cell subsets may vary

  • Impact: Target engagement requirements may differ between preclinical and clinical studies

Strategic Approaches for Translational Research:

• Multi-species Testing:

  • Test compounds against both mouse and human receptors early in development

  • Calculate species selectivity ratios to identify potential translational challenges

• Humanized Mouse Models:

  • Consider using humanized mouse models expressing human H4R for more predictive efficacy studies

  • Alternatively, use species-specific pharmacodynamic biomarkers

• Pharmacological Equivalence Strategy:

• Case Study - JNJ7777120:
  JNJ7777120 shows how these differences manifest in practice:

  • In human H4R: Acts as an inverse agonist with high affinity (5-10 nM)

  • In mouse Hrh4: Acts as a neutral antagonist with somewhat lower affinity

  • These differences necessitate careful dose selection when moving between species

Understanding these species differences is essential when interpreting preclinical data and designing clinical trials, particularly for conditions like asthma and pruritus where H4R antagonists show therapeutic potential .

What role does mouse Hrh4 play in immune cell function and inflammatory diseases?

Mouse Hrh4 serves as a critical modulator of immune responses with particular importance in:

Macrophage Function:

• Chemotaxis: Hrh4 activation induces macrophage migration toward histamine gradients

• Activation: Promotes M1 differentiation and phagocytosis

• Cytokine production: Induces secretion of pro-inflammatory cytokines and VEGF

In Diabetic Retinopathy:
Flow cytometry analysis revealed that Hrh4-expressing macrophages are the predominant immune cells infiltrating the retina in STZ-induced diabetic mice . The pathophysiological cascade involves:

• Hyperglycemia induces upregulation of Hrh4 expression on macrophages

• Histamine promotes chemotaxis of these macrophages into retinal tissue through Hrh4

• Infiltrating macrophages secrete inflammatory mediators (IL-6) and VEGF

• These factors increase vascular permeability and contribute to pathological vessel leakage

Therapeutic Intervention Data:
Treatment with the Hrh4 antagonist JNJ7777120 in the STZ-induced diabetic mouse model showed:

These findings demonstrate that Hrh4 antagonism effectively reduces inflammation and pathological vessel leakage in diabetic retinopathy .

Beyond Retinopathy:
Mouse models further implicate Hrh4 in multiple inflammatory and allergic conditions:

• Pruritus: Hrh4-deficient mice show reduced scratching in response to histamine

• Asthma: Hrh4 antagonism reduces lung inflammation and eosinophil/lymphocyte infiltration

• Dermatitis: Hrh4 mediates immune cell recruitment in skin inflammation models

The selective expression of Hrh4 on immune cells makes it a promising therapeutic target for inflammatory conditions with fewer potential side effects compared to antagonists of more widely expressed histamine receptors.

How can site-directed mutagenesis be used to investigate structure-function relationships in mouse Hrh4?

Site-directed mutagenesis provides powerful insights into structure-function relationships of mouse Hrh4:

Methodological Approach:

• Target Selection Strategy:

  • Identify key residues through sequence alignment with human H4R and other species

  • Focus on divergent residues in transmembrane domains and binding pockets

  • Prioritize residues implicated in constitutive activity (e.g., V171, M181)

• Mutagenesis Protocol:

  • Use pVL1392 plasmids containing mHrh4 as templates

  • Design primers with ~30 bp overlap and the desired mutation

  • Perform PCR-based site-directed mutagenesis

  • Verify mutations by sequencing

• Expression and Characterization:

  • Co-express wild-type or mutant receptors with Gαi2 and Gβ1γ2 in Sf9 cells

  • Prepare membranes for binding and functional studies

  • Compare pharmacological profiles using [³H]-histamine binding and [³⁵S]-GTPγS functional assays

Key Structure-Function Insights:

• Constitutive Activity Determinants:
  A systematic mutagenesis study revealed:

  Receptor/Mutant	Constitutive Activity	Impact on Ligand Binding	Signaling Efficiency
  Human H4R (wild-type)	High	Reference	Reference
  Mouse H4R (wild-type)	Low	Similar Kd for histamine	Reduced basal activity
  mH4R-V171F	Increased	Minor changes	Intermediate
  mH4R-V171F+M181S	Significantly increased	Minor changes	Approaches human H4R

  The V171F mutation (corresponding to F169 in human) partially restores constitutive activity in mouse Hrh4, indicating its critical role in stabilizing active receptor conformations .

• Ligand Binding Pocket Mapping:
  Mutations in the predicted binding pocket can reveal:

  • Residues essential for histamine recognition

  • Determinants of antagonist selectivity

  • Species-specific differences in ligand affinity

• G-protein Coupling Interface:
  Mutations in intracellular loops and C-terminal domains can identify:

  • Key residues for Gαi coupling specificity

  • Determinants of signaling efficacy

  • β-arrestin recruitment sites

Application to Drug Discovery:
Structure-function studies using site-directed mutagenesis enable:

• Design of compounds with improved species cross-reactivity

• Development of biased ligands that selectively activate certain pathways

• Prediction of drug resistance mutations

By systematically mutating residues that differ between mouse and human H4R, researchers can create mouse models that more accurately predict human drug responses and develop compounds with improved translational potential from preclinical to clinical stages.

How can I optimize expression systems for functional studies of recombinant mouse Hrh4?

Optimizing expression systems for functional studies of mouse Hrh4 requires careful consideration of multiple factors:

Expression System Selection and Optimization:

• Cell Line Selection Guide:

• Vector Design Optimization:

  • Include strong promoters (CMV for mammalian, polyhedrin for insect cells)

  • Incorporate Kozak sequence for efficient translation initiation

  • Consider adding N-terminal signal sequences to improve membrane targeting

  • For purification, include cleavable affinity tags (His, FLAG, etc.)

• Transfection Protocol Refinement:

  • For transient expression in HEK293:

    • Lipid-based transfection at 70-80% confluency

    • Harvest cells 48 hours post-transfection

    • Use serum-free media during transfection

  • For stable cell line generation:

    • Select optimal antibiotic concentration through kill curve analysis

    • Use single-cell cloning to isolate high expressors

    • Validate receptor expression by radioligand binding

• Functional Coupling Enhancement:

  • Co-express appropriate G-proteins (Gαi2, Gβ1γ2) for optimal coupling

  • For calcium signaling assays, co-express chimeric G-proteins (Gαqi5)

  • For arrestin recruitment, consider fusion constructs with luciferase or fluorescent proteins

Quality Control Metrics:
Before proceeding to functional assays, validate expression using:

• Receptor density quantification via saturation binding

• Immunoblotting for tagged constructs

• Plasma membrane localization via confocal microscopy

• Response to known agonists and antagonists

By optimizing these parameters, researchers can achieve consistent expression of functional mouse Hrh4 with pharmacological properties matching the native receptor, enabling reliable screening and characterization of novel compounds targeting this receptor.

How do I address species differences when designing inhibitor studies for mouse versus human Hrh4?

Addressing species differences is crucial when designing inhibitor studies that can translate between mouse models and human applications:

Comprehensive Cross-Species Characterization Strategy:

• Parallel Pharmacological Profiling:

  • Test compounds against both mouse and human receptors under identical conditions

  • Determine affinity (Ki values) through competition binding assays

  • Assess functional responses (antagonism, inverse agonism) in [³⁵S]-GTPγS assays

  • Calculate species selectivity index (Ki mouse/Ki human)

• Species-Specific Pharmacological Data for Key H4R Antagonists:

• Dose Adjustment Strategies:

  • For mouse studies predicting human efficacy, adjust dosing based on:

    • Receptor affinity differences (typically 3-4× higher for mouse Hrh4)

    • Differences in constitutive activity (may affect antagonist vs. inverse agonist activity)

    • Potential differences in drug metabolism and distribution

  • Target receptor occupancy rather than absolute dose

• Addressing Constitutive Activity Differences:

  • Human H4R: High constitutive activity makes inverse agonists particularly effective

  • Mouse Hrh4: Low constitutive activity means inverse agonism contributes little to efficacy

  • Solution: Focus on target engagement and competitive antagonism in mouse studies

  • Alternative: Consider using humanized mouse models for testing inverse agonists

• Critical Controls for Valid Cross-Species Comparison:

  • Include reference compounds with known species differences

  • Use receptor occupancy studies to normalize doses

  • Validate in vivo target engagement using ex vivo binding assays

  • Perform parallel PK/PD studies to account for species differences in drug metabolism

Practical Application in Diabetic Retinopathy Research:
When studying JNJ7777120 as a therapeutic agent for diabetic retinopathy in mice , researchers should:

• Use doses 3-4× higher than would be calculated from human receptor affinity

• Focus on antagonist activity (blocking histamine-induced macrophage infiltration) rather than inverse agonist effects

• Design dosing regimens that maintain sufficient receptor occupancy throughout the treatment period

• Include appropriate controls to distinguish receptor-mediated from off-target effects

By systematically addressing these species differences, researchers can design more predictive preclinical studies and improve the translational value of mouse models for H4R-targeted drug discovery.

What are emerging research areas involving mouse Hrh4 beyond inflammation and allergy?

While mouse Hrh4 has been extensively studied in inflammation and allergy, several emerging research areas show promise:

Neurological Disorders:
Recent findings suggest potential roles for Hrh4 in:

• Neuroinflammation associated with neurodegenerative diseases

• Microglial activation and polarization

• Blood-brain barrier integrity during inflammatory conditions

The selective upregulation of Hrh4 in activated microglia may provide a novel therapeutic target for conditions like Alzheimer's disease, multiple sclerosis, and stroke.

Cancer Immunology:
Emerging evidence points to Hrh4 involvement in:

• Tumor-associated macrophage function and polarization

• Immune checkpoint regulation and tumor microenvironment

• Myeloid-derived suppressor cell recruitment

Given that Hrh4 antagonists can modify macrophage infiltration and activation , they might represent a novel approach to cancer immunotherapy by reprogramming the tumor immune microenvironment.

Metabolic Diseases:
Beyond the established role in diabetic retinopathy , Hrh4 may influence:

• Adipose tissue inflammation in obesity

• Macrophage-mediated insulin resistance

• Non-alcoholic steatohepatitis progression

Regenerative Medicine:
Preliminary evidence suggests Hrh4 may regulate:

• Macrophage polarization during wound healing

• Tissue remodeling after injury

• Stem cell recruitment and differentiation

Potential Research Approaches:

• Generate tissue-specific conditional Hrh4 knockout mice

• Develop novel biased ligands that selectively modulate specific signaling pathways

• Combine Hrh4 targeting with established therapies to enhance therapeutic outcomes

• Explore Hrh4 as a biomarker for disease progression or treatment response

These emerging areas represent significant opportunities for researchers to expand the understanding of Hrh4 biology beyond its established roles in inflammation and allergy.

How can advanced structural biology techniques enhance our understanding of mouse Hrh4?

Advanced structural biology techniques offer unprecedented opportunities to understand mouse Hrh4 at the molecular level:

Cryo-Electron Microscopy (Cryo-EM):

• Allows visualization of receptor-G protein complexes in different activation states

• Can reveal subtle differences between mouse and human H4R structures

• Enables mapping of species-specific amino acids onto 3D structures

• Methodology: Express and purify stabilized mouse Hrh4 in complex with mini-G proteins or nanobodies

X-ray Crystallography:

• Provides high-resolution structures for ligand binding pocket analysis

• Requires receptor stabilization through:

  • Thermostabilizing mutations

  • Fusion partners (T4 lysozyme, BRIL)

  • Conformational stabilization with high-affinity ligands

• Can be particularly useful for fragment-based drug discovery

Molecular Dynamics Simulations:

• Model receptor dynamics in physiological membrane environments

• Compare conformational equilibria between mouse and human receptors

• Investigate the molecular basis for differences in constitutive activity

• Predict binding modes for novel ligands

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

• Provides information about protein dynamics and conformational changes

• Can identify regions with altered flexibility between species variants

• Useful for mapping allosteric effects of ligand binding

Structure-Based Applications:

• Drug Design:

  • Structure-guided design of species-independent antagonists

  • Development of biased ligands that selectively activate certain pathways

  • Creation of highly selective compounds with reduced off-target effects

• Mechanism of Constitutive Activity:
  Understanding the structural basis for the different constitutive activity between mouse and human H4R could:

  • Reveal general principles of GPCR activation

  • Identify "molecular switches" that control basal activity

  • Provide insights applicable to other constitutively active GPCRs

• Species Differences Mapping:
  Structural comparison between mouse and human H4R could:

  • Identify critical regions for species-selective pharmacology

  • Guide the design of humanized mouse models with improved predictive value

  • Enhance translational research by explaining pharmacological differences

Integrating these structural approaches with functional studies can significantly accelerate H4R-targeted drug discovery and provide fundamental insights into GPCR biology.

What novel therapeutic applications might emerge from targeting mouse Hrh4 in disease models?

Targeting mouse Hrh4 in disease models is uncovering several promising therapeutic applications beyond the established roles in allergy and pruritus:

Diabetic Complications:
The demonstrated efficacy of Hrh4 antagonism in diabetic retinopathy suggests potential in:

• Diabetic nephropathy, where macrophage infiltration drives progression

• Diabetic neuropathy, potentially addressing neuroinflammatory components

• Diabetic wound healing, modulating inflammatory phenotypes to promote resolution

Autoinflammatory Disorders:
Targeting macrophage recruitment and activation via Hrh4 offers potential in:

• Inflammatory bowel disease, particularly macrophage-driven pathologies

• Rheumatoid arthritis, where synovial macrophages contribute to joint destruction

• Systemic lupus erythematosus, potentially modulating aberrant immune activation

Fibrotic Diseases:
Given the role of macrophages in fibrotic processes, Hrh4 antagonists may help in:

• Pulmonary fibrosis, reducing macrophage-driven fibrotic transformation

• Liver fibrosis, modulating inflammatory responses that drive stellate cell activation

• Cardiac fibrosis following myocardial infarction

Combination Therapy Approaches:
Novel therapeutic strategies may include:

Delivery Innovations:
Novel delivery approaches for Hrh4-targeted therapeutics:

• Nanoparticle formulations with macrophage-specific targeting

• Extended-release implants for chronic conditions like diabetic retinopathy

• Topical formulations for skin conditions to minimize systemic exposure

Biomarker-Guided Therapy:
Development of companion diagnostics to identify patients likely to respond:

• Histamine levels in relevant tissues

• Hrh4 expression profiles on circulating immune cells

• Genetic polymorphisms affecting Hrh4 expression or function

The unique expression pattern of Hrh4, predominantly on immune cells , provides an opportunity for selective immune modulation with potentially fewer off-target effects than broader immunomodulatory approaches, making it an attractive target for these diverse therapeutic applications.